RemeGen's Telitacicept Approved for Myasthenia Gravis in China
CompanyDrug

RemeGen’s Telitacicept Approved for Myasthenia Gravis in China

Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases
CompanyDeals

Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases

HKSH Medical Partners with United Imaging to Advance CT Technology
CompanyDeals

HKSH Medical Partners with United Imaging to Advance CT Technology

AstraZeneca's Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
CompanyDrug

AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment

EyePoint's Partner Betta Completes Enrollment for Duravyu's Pivotal Phase III Study
CompanyDrug

EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
CompanyDrug

EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment

AbelZeta Pharma's C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
CompanyDrug

AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments

FDA Rejects Data from Two Chinese Testing Labs Over Compliance Concerns
Policy / Regulatory

FDA Rejects Data from Two Chinese Testing Labs Over Compliance Concerns

CARsgen's Satricabtagene Autoleucel Granted Priority Review by China's CDE
CompanyDrug

CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE

Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension
CompanyDrug

Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension

Nhwa Pharmaceutical Jiangsu Haoxinqing Overseas Listing
CompanyDeals

Jiangsu Nhwa’s Investee Jiangsu Haoxinqing Plans Overseas Listing

Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center
CompanyDeals

Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center